Exclusive: Perceptic, a startup automating drug discovery end-to-end for Big Pharma, emerges from stealth with $12 million in seed funding
Perceptic, a startup founded by former Palantir executives, has launched an AI platform for drug development and secured $12 million in seed funding. The company aims to streamline the drug discovery process by integrating various AI tools and data sources used by pharmaceutical companies. With its software already in use by top-tier firms, Perceptic is positioning itself as a comprehensive solution for the complexities of drug development.
- ▪Perceptic has developed an end-to-end AI platform for drug development.
- ▪The startup raised $12 million in seed funding led by Accel.
- ▪Perceptic's software is already being utilized by multiple pharmaceutical companies, including CSL.
- ▪The platform aims to connect various AI tools and data sources to improve drug discovery efficiency.
- ▪Perceptic focuses on scouting external assets, selecting clinical trial indications, and building a data foundation for trial design.
Opening excerpt (first ~120 words) tap to expand
A trio of former Palantir executives who helped spearhead that company’s Life Sciences practice have founded a startup called Perceptic that is building an end-to-end AI platform for drug development, handling everything from drug discovery to clinical trial design. The company emerged from stealth today and announced a $12 million seed funding round. London-based venture capital firm Accel led the funding round, alongside Air Street Capital and Elder Gull. The company’s valuation following the funding round was not disclosed. Perceptic said its software is already being used by multiple top-tier pharmaceutical companies, though it was only allowed to name CSL, the Australian biotechnology company. In the past two years, numerous startups have sprung up to use AI to speed drug discovery.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fortune.
Discussion
0 commentsMore from Fortune
